

It is hereby certified that a patent has been granted to the patentee for an invention entitled A PHARMACEUTICAL COMPOSITION FOR ANAEMIA as disclosed in the above mentioned application for the term of 20 years from the 9th day of March 2018 in accordance with the provisions of the Patents Act, 1970.

INTELLECTUAL ROPERTY INDIA Is DESIGNS TRADE MARKS GRAPHICAL INDICATION

अनुदान की तारीख : 29/11/2021 Date of Grant :

टिपप्पी - इस पेटेंट के नवीकरण के लिए फीस, घरि इसे बनाए रखा जाना है, **9th day of March 2020** को और उसके प्रचता प्रत्येक वर्ष मे उसी दिन देश सैगी। Note. - The fees for renewal of this patent, if it is to be maintained will fall / has fallen due on 9th day of March 2020 and on the same da in every year thereafter.

> Now Patented in INDIA

Also Patented in Australia, Canada, Malaysia, OAPI, Nigeria, and Ukraine

OAPI - AFRICAN INTELLECTUAL PROPERTY ORGANIZATION

<u>La Renon</u>

The Makers of...

FERRONEMIA

Lactoferrin 100 mg & Disodium Guanosine 5-Monophosphate 10 mg Tablets

FERRONEMIA PLUS

Lactoferrin 50 mg, Disodium Guanosine 5-monophosphate 5 mg and Elemental Iron (Ferrous Bisglycinate) 19 mg Tablets **FERRONEMIA**

Lactoferrin100 mg and Disodium Guanosine 5-Monophosphate10 mg Tablets

FERRONEMIA PLUS

Lactoferrin 50 mg, Disodium Guanosine 5-Monophosphate 5 mg and Elemental Iron Ferrous Bisglycinate (FBG) 19 mg Tablets

Description:

Lactoferrin is a non-haem iron-binding protein that is part of the transferrin protein family and differs from transferrin by its higher affinity for iron which is 300 times greater and its ability to retain iron at a pH lower than 4 such as exist. (e.g. in the gastrointestinal tract or inflammatory lesions).

Disodium Guanosine 5-Monophosphate is a salt of Guanosine 5-Monophosphate. Ribonucleoside Monophosphate which upon phosphorylation to GTP becomes incorporated into ribonucleic acid (RNAs) by various RNA polymerase(s).

Ferrous bisglycinate (FBG) is a chelate that is used as a source of dietary iron. Forming a ring structure when reacting with glycine, ferrous bisglycinate acts as both a chelate and a nutritionally functional.

Indication :

FERRONEMIA and **FERRONEMIA PLUS** is indicated for the management of Iron Deficiency Anemia and Anemia of Chronic Disease.

Mechanism of Action :

FERRONEMIA and FERRONEMIA PLUS work by the following mechanisms :

- 1. Decrease Hepcidin levels by regulating the Ferroportin Hepcidin Axis
- 2. Increase iron efflux in the systemic circulation by Macrophage M1 to M2 phenotype conversion
- 3. Reduce ferritin bound iron stores
- 4. Reduce inflammatory pathways further affecting Hepcidin
- 5. Improve Ferroportin stabilization via GMP

Dosage & Administration :

1-2 Tablets a day or as suggested by Healthcare Professional.

Advantages of FERRONEMIA & FERRONEMIA PLUS in CKD Patients :

- 1. Effective increase of Hemoglobin and systemic Iron Levels
- 2. Countering any adverse effect of inflammation arising due to Erythropoietin resistance
- 3. Less likely to cause intestinal side effects such as nausea, constipation and bloating
- 4. Restoration of Iron Homeostasis
- 5. Ferrous bisglycinate has at least two-fold higher biovailability/absorption compared to "conventional" iron salts, e.g., ferrous sulfate and ferrous fumarate.
- 6. Useful in the treatment of both True/absolute iron deficiency anemia as well as Functional Iron deficiency anemia

Frimline Private Limited

(A Subsidiary of La Renon Healthcare Private Limited) 5th Floor, 511-ISCON Elegance | Circle P | Prahlad Nagar Cross Roads | S.G.Highway Ahmedabad - 380015 | Gujarat | India Phone: +91-79-6616-8999 | E-mail: info@frimline.com | Web: www.frimline.com

4	l am:
	Call me on:
	Mail me at:

©2021 All rights reserved, Frimline Private Limited